Transcriptomics

Dataset Information

0

Extracellular matrix targeted mRNA profiles of PKN2 KO/WT mouse pancreatic stellate cell lines (PSCs) treated with TGF-b or vehicle control


ABSTRACT: In pancreatic ductal adenocarcinoma (PDAC), differentiation of pancreatic stellate cells (PSCs) into myofibroblast-like cancer-associated fibroblasts (CAFs) promotes fibrotic, therapy-resistant tumours. Conversely, suppression of CAFs can result in aggressive metastatic tumours. Here we show that the Rho-effector kinase protein kinase N2 (PKN2) is critical for PSC myofibroblast differentiation. Loss of PKN2 was associated with reduced PSC proliferation and contractility, retention of lipid droplets and decreased a-SMA stress fibres. PKN2 loss was also associated with a myofibroblast CAF to -like inflammatory CAF switch in the PSC matrisome signature both in vitro and in vivo. In spheroid co-cultures with PDAC cells, loss of PKN2 prevented PSC invasion but, counter-intuitively, promoted invasive cancer cell outgrowth. Further, deletion of PKN2 in the pancreatic stroma induced more locally invasive, orthotopic pancreatic tumours. Finally, we demonstrated that a PKN2KO PKN2 KO matrisome signature predicts poor outcome in pancreatic and other solid human cancers. Our data indicate that suppressing PSC myofibroblast differentiation function can limit important stromal tumour suppressive mechanisms, while promoting a switch to a cancer-supporting CAF phenotype.

ORGANISM(S): Mus musculus

PROVIDER: GSE189245 | GEO | 2021/11/22

REPOSITORIES: GEO

Similar Datasets

2021-11-19 | GSE189027 | GEO
| phs001840 | dbGaP
2022-08-23 | GSE197908 | GEO
2020-02-18 | PXD008276 | Pride
2021-04-15 | GSE172096 | GEO
2023-09-18 | GSE223205 | GEO
2021-10-19 | GSE185750 | GEO
2024-02-28 | GSE253559 | GEO
2024-02-28 | GSE253558 | GEO
2020-09-30 | GSE155442 | GEO